A Phase Ib/II Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330, Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer

Trial Profile

A Phase Ib/II Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330, Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer

Suspended
Phase of Trial: Phase I/II

Latest Information Update: 08 Apr 2017

At a glance

  • Drugs Selinexor (Primary) ; Gemcitabine; Paclitaxel
  • Indications Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 31 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
    • 31 Jan 2017 Status changed from recruiting to suspended.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top